PARP1 and neoplasm: Indeed, the widespread use of germline and tumor DNA sequencing and the approval of PARP inhibitors in everyday clinical practice have led to a greater number of patients harboring BRCA 1/2 mutated ovarian tumors being treated with platinum agents and/or PARPis, on one hand, and to the problem of acquired resistance to these therapeutic regimens, on the other hand.